title: [Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer].
abstract: The study compares letrozole (Femara and aminoglutethimide (AG), a standard therapy for postmenopausal women with advanced breast cancer, previously treated with anti-estrogens. 555 women were randomly assigned letrozole 2.5 mg once daily (n = 185), letrozole 0.5 mg once daily (n = 192) or aminoglutethimide 250 mg twice daily with corticosteroid support (n = 178) in an open-label, multicenter trial. The primary end-point was objective response rate (ORR), with time events as secondary. ORR was analysed nine months after enrollment of the last patient, while survival was analysed 15 months after the last patients was enrolled. We report the results of these analyses plus an extended period of observation (covering a total duration of approximately 45 months) to determine the duration of response and clinical benefit. Overall objective response rates (complete + partial) of 19.5%, 16.7% and 12.4% were seen for letrozole 2.5 mg, 0.5 mg and AG respectively. Median duration of response and stable disease was longest for letrozole 2.5 mg (21 months) compared with letrozole 0.5 mg (18 months) and AG (14 months). Letrozole 2.5 mg was superior to AG in time to progression, time to treatment failure and overall survival. Treatment-related adverse events occurred in fewer patients on letrozole (33%) than on AG (46%). Letrozole 2.5 mg offers longer disease control than aminoglutethimide and letrozole 0.5 mg in the treatment of postmenopausal women with advanced breast cancer, previously treated with anti-estrogens.
authors.affiliation: N.N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St. Petersburg, Russia.
authors.forename: M
authors.initials: M
authors.lastname: Gershanovich
authors.forename: Kh
authors.initials: Kh
authors.lastname: Chaudri
authors.forename: D
authors.initials: D
authors.lastname: Campos
authors.forename: H
authors.initials: H
authors.lastname: Lurie
authors.forename: A
authors.initials: A
authors.lastname: Bonaventura
authors.forename: M
authors.initials: M
authors.lastname: Jeffrey
authors.forename: F
authors.initials: F
authors.lastname: Buzzi
authors.forename: I
authors.initials: I
authors.lastname: Bodrogi
authors.forename: H
authors.initials: H
authors.lastname: Ludwig
authors.forename: P
authors.initials: P
authors.lastname: Reichard
authors.forename: N O
authors.initials: NO
authors.lastname: O'Higgins
authors.forename: G
authors.initials: G
authors.lastname: Romieu
authors.forename: P
authors.initials: P
authors.lastname: Friedrich
authors.forename: M
authors.initials: M
authors.lastname: Lassus
mesh_terms: D000368:Aged; D000616:Aminoglutethimide / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000077289:Letrozole; D008875:Middle Aged; D009570:Nitriles / Q000627:therapeutic use*; D016019:Survival Analysis; D017211:Treatment Failure; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D009570:Nitriles; D014230:Triazoles; D000616:Aminoglutethimide; D000077289:Letrozole